Beyond affinity: selection of antibody variants with optimal biophysical properties and reduced immunogenicity from mammalian display libraries

References

• Kaplon H, Muralidharan M, Schneider Z, Reichert JM. Antibodies to watch in 2020. mAbs. 2020;12:1703531.
   PubMed Web of Science ®Google Scholar
• Wörn A, Plückthun A. Stability engineering of antibody single-chain Fv fragments1. J Mol Biol. 2001;305(5):989–18. doi:https://doi.org/10.1006/jmbi.2000.4265.
   PubMed Web of Science ®Google Scholar
• Dudgeon K, Rouet R, Kokmeijer I, Schofield P, Stolp J, Langley D, Stock D, Christ D. General strategy for the generation of human antibody variable domains with increased aggregation resistance. Proc Natl Acad Sci U S A. 2012;109(27):10879–84. doi:https://doi.org/10.1073/pnas.1202866109.
   PubMed Web of Science ®Google Scholar
• Famm K, Hansen L, Christ D, Winter G. Thermodynamically stable aggregation-resistant antibody domains through directed evolution. J Mol Biol. 2008;376(4):926–31. doi:https://doi.org/10.1016/j.jmb.2007.10.075.
   PubMed Web of Science ®Google Scholar
• Jain T, Sun T, Durand S, Hall A, Houston NR, Nett JH, Sharkey B, Bobrowicz B, Caffry I, Yu Y. Biophysical properties of the clinical-stage antibody landscape. Proc Natl Acad Sci U S A. 2017;114(5):944–49. doi:https://doi.org/10.1073/pnas.1616408114.
   PubMed Web of Science ®Google Scholar
• Starr CG, Tessier PM. Selecting and engineering monoclonal antibodies with drug-like specificity. Curr Opin Biotechnol. 2019;60:119–27.
   PubMed Web of Science ®Google Scholar
• Parthiban K, Perera RL, Sattar M, Huang Y, Mayle S, Masters E, Griffiths D, Surade S, Leah R, Dyson MR, et al. A comprehensive search of functional sequence space using large mammalian display libraries created by gene editing. mAbs. 2019;11(5):884–98. doi:https://doi.org/10.1080/19420862.2019.1618673.
   PubMed Web of Science ®Google Scholar
• Ratanji KD, Derrick JP, Dearman RJ, Kimber I. Immunogenicity of therapeutic proteins: influence of aggregation. J Immunotoxicol. 2014;11(2):99–109. doi:https://doi.org/10.3109/1547691X.2013.821564.
   PubMed Web of Science ®Google Scholar
• Moussa EM, Panchal JP, Moorthy BS, Blum JS, Joubert MK, Narhi LO, Topp EM. Immunogenicity of therapeutic protein aggregates. J Pharm Sci. 2016;105(2):417–30. doi:https://doi.org/10.1016/j.xphs.2015.11.002.
   PubMed Web of Science ®Google Scholar
• Nabhan M, Pallardy M, Turbica I. Immunogenicity of bioproducts: cellular models to evaluate the impact of therapeutic antibody aggregates. Front Immunol. 2020;11:1664–3224. doi:https://doi.org/10.3389/fimmu.2020.00725.
   PubMedGoogle Scholar
• Ridker PM, Tardif J-C, Amarenco P, Duggan W, Glynn RJ, Jukema JW, Kastelein JJP, Kim AM, Koenig W, Nissen S. Lipid-reduction variability and antidrug-antibody formation with bococizumab. N Engl J Med. 2017;376(16):1517–26. doi:https://doi.org/10.1056/NEJMoa1614062.
   PubMed Web of Science ®Google Scholar
• Carr FJ, Baker MP. Recombinant antibodies for immunotherapy. In Little M, ed. Cambridge: Cambridge University Press; 2009. pp. 43–52.
   Google Scholar
• Buchanan A, Clementel V, Woods R, Harn N, Bowen MA, Mo W, Popovic B, Bishop SM, Dall’Acqua W, Minter R, et al. Engineering a therapeutic IgG molecule to address cysteinylation, aggregation and enhance thermal stability and expression. mAbs. 2013;5(2):255–62. doi:https://doi.org/10.4161/mabs.23392.
   PubMed Web of Science ®Google Scholar
• Dobson CL, Devine PWA, Phillips JJ, Higazi DR, Lloyd C, Popovic B, Arnold J, Buchanan A, Lewis A, Goodman J, et al. Engineering the surface properties of a human monoclonal antibody prevents self-association and rapid clearance in vivo. Sci Rep. 2016;6(1):38644. doi:https://doi.org/10.1038/srep38644.
   PubMed Web of Science ®Google Scholar
• Bethea D, Wu S-J, Luo J, Hyun L, Lacy ER, Teplyakov A, Jacobs SA, O’Neil KT, Gilliland GL, Feng Y, et al. Mechanisms of self-association of a human monoclonal antibody CNTO607. Protein Eng Des Sel. 2012;25(10):531–38. doi:https://doi.org/10.1093/protein/gzs047.
   PubMed Web of Science ®Google Scholar
• Jacobs SA, Wu SJ, Feng Y, Bethea D, O’Neil KT. Cross-interaction chromatography: A rapid method to identify highly soluble monoclonal antibody candidates. Pharm Res. 2010;27(1):65–71. doi:https://doi.org/10.1007/s11095-009-0007-z.
   PubMed Web of Science ®Google Scholar
• Nobbmann U, Connah M, Fish B, Varley P, Gee C, Mulot S, Chen J, Zhou L, Lu Y, Sheng F, et al. Dynamic light scattering as a relative tool for assessing the molecular integrity and stability of monoclonal antibodies. Biotechnol Genet Eng Rev. 2007;24(1):117–28. doi:https://doi.org/10.1080/02648725.2007.10648095.
   PubMedGoogle Scholar
• Chao G, Lau WL, Hackel BJ, Sazinsky SL, Lippow SM, Wittrup KD. Isolating and engineering human antibodies using yeast surface display. Nat Protoc. 2006;1(2):755–68. doi:https://doi.org/10.1038/nprot.2006.94.
   PubMed Web of Science ®Google Scholar
• van den Beucken T. Affinity maturation of fab antibody fragments by fluorescent-activated cell sorting of yeast-displayed libraries. FEBS Lett. 2003;546:288–94.
   PubMed Web of Science ®Google Scholar
• Ferri N, Corsini A, Sirtori CR, Ruscica M. Bococizumab for the treatment of hypercholesterolaemia. Expert Opin Biol Ther. 2017;17(2):237–43. doi:https://doi.org/10.1080/14712598.2017.1279602.
   PubMed Web of Science ®Google Scholar
• Liang H, Chaparro-Riggers J, Strop P, Geng T, Sutton JE, Tsai D, Bai L, Abdiche Y, Dilley J, Yu J. Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates. J Pharmacol Exp Ther. 2012;340(2):228. doi:https://doi.org/10.1124/jpet.111.187419.
   PubMed Web of Science ®Google Scholar
• Sun A, Benet LZ. Late-stage failures of monoclonal antibody drugs: a retrospective case study analysis. Pharmacology. 2020;105(3–4):145–63. doi:https://doi.org/10.1159/000505379.
   PubMed Web of Science ®Google Scholar
• Dyson MR, Shadbolt SP, Vincent KJ, Perera RL, McCafferty J. Production of soluble mammalian proteins in Escherichia coli: identification of protein features that correlate with successful expression. BMC Biotechnol. 2004;4(1):32. doi:https://doi.org/10.1186/1472-6750-4-32.
   PubMedGoogle Scholar
• Kelly RL, Yu Y, Sun T, Caffry I, Lynaugh H, Brown M, Jain T, Xu Y, Wittrup KD. Target-independent variable region mediated effects on antibody clearance can be FcRn independent. mAbs. 2016;8(7):1269–75. doi:https://doi.org/10.1080/19420862.2016.1208330.
   PubMed Web of Science ®Google Scholar
• Liu Y, Caffry I, Wu J, Geng SB, Jain T, Sun T, Reid F, Cao Y, Estep P, Yu Y, et al. High-throughput screening for developability during early-stage antibody discovery using self-interaction nanoparticle spectroscopy. mAbs. 2014;6(2):483–92. doi:https://doi.org/10.4161/mabs.27431.
   PubMed Web of Science ®Google Scholar
• Jones TD, Crompton LJ, Carr FJ, Baker MP. Therapeutic antibodies: methods and protocols. In Dimitrov AS, ed. Totowa (NJ): Humana Press; 2009. pp. 405–23.
   Google Scholar
• Wullner D, Zhou L, Bramhall E, Kuck A, Goletz TJ, Swanson S, Chirmule N, Jawa V. Considerations for optimization and validation of an in vitro PBMC derived T cell assay for immunogenicity prediction of biotherapeutics. Clin Immunol. 2010;137(1):5–14. doi:https://doi.org/10.1016/j.clim.2010.06.018.
   PubMed Web of Science ®Google Scholar
• Walsh RE, Lannan M, Wen Y, Wang X, Moreland CA, Willency J, Knierman MD, Spindler L, Liu L, Zeng W. Post-hoc assessment of the immunogenicity of three antibodies reveals distinct immune stimulatory mechanisms. mAbs. 2020;12(1):1764829. doi:https://doi.org/10.1080/19420862.2020.1764829.
   PubMed Web of Science ®Google Scholar
• Paul S, Kolla RV, Sidney J, Weiskopf D, Fleri W, Kim Y, Peters B, Sette A. Evaluating the immunogenicity of protein drugs by applying in vitro mhc binding data and the immune epitope database and analysis resource. Clin Dev Immunol. 2013;2013:467852–467852. doi:https://doi.org/10.1155/2013/467852.
   PubMedGoogle Scholar
• Vita R, Mahajan S, Overton JA, Dhanda SK, Martini S, Cantrell JR, Wheeler DK, Sette A, Peters B. The immune epitope database (IEDB): 2018 update. Nucleic Acids Res. 2018;47(D1):D339–D343. doi:https://doi.org/10.1093/nar/gky1006.
   Web of Science ®Google Scholar
• Paul S, Lindestam Arlehamn CS, Scriba TJ, Dillon MBC, Oseroff C, Hinz D, McKinney DM, Carrasco Pro S, Sidney J, Peters B. Development and validation of a broad scheme for prediction of HLA class II restricted T cell epitopes. J Immunol Methods. 2015;422:28–34. doi:https://doi.org/10.1016/j.jim.2015.03.022.
   PubMed Web of Science ®Google Scholar
• Dhanda SK. Predicting HLA CD4 immunogenicity in human populations. Front Immunol. 2018;9:1369.
   PubMed Web of Science ®Google Scholar
• Gandhi M, Alwawi E, Gordon KB. Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis. Semin Cutan Med Surg. 2010;29(1):48–52. doi:https://doi.org/10.1016/j.sder.2010.02.001.
   PubMed Web of Science ®Google Scholar
• Schoch A, Kettenberger H, Mundigl O, Winter G, Engert J, Heinrich J, Emrich T. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics. Proc Natl Acad Sci U S A. 2015;112(19):5997–6002. doi:https://doi.org/10.1073/pnas.1408766112.
   PubMed Web of Science ®Google Scholar
• Xu Y, Roach W, Sun T, Jain T, Prinz B, Yu T-Y, Torrey J, Thomas J, Bobrowicz P, Vasquez M. Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool. Protein Engineering Design and Selection. 2013;26(10):663–70. doi:https://doi.org/10.1093/protein/gzt047.
   PubMed Web of Science ®Google Scholar
• Kelly RL, Le D, Zhao J, Wittrup KD. Reduction of nonspecificity motifs in synthetic antibody libraries. J Mol Biol. 2018;430(1):119–30. doi:https://doi.org/10.1016/j.jmb.2017.11.008.
   PubMed Web of Science ®Google Scholar
• Kelly RL, Geoghegan JC, Feldman J, Jain T, Kauke M, Le D, Zhao J, Wittrup KD. Chaperone proteins as single component reagents to assess antibody nonspecificity. mAbs. 2017;9(7):1036–40. doi:https://doi.org/10.1080/19420862.2017.1356529.
   PubMed Web of Science ®Google Scholar
• Datta-Mannan A, Thangaraju A, Leung D, Tang Y, Witcher DR, Lu J, Wroblewski VJ. Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics. mAbs. 2015;7(3):483–93. doi:https://doi.org/10.1080/19420862.2015.1016696.
   PubMed Web of Science ®Google Scholar
• Hötzel I, Theil F-P, Bernstein LJ, Prabhu S, Deng R, Quintana L, Lutman J, Sibia R, Chan P, Bumbaca D. A strategy for risk mitigation of antibodies with fast clearance. mAbs. 2012;4(6):753–60. doi:https://doi.org/10.4161/mabs.22189.
   PubMed Web of Science ®Google Scholar
• Zhang H, Wilson IA, Lerner RA. Selection of antibodies that regulate phenotype from intracellular combinatorial antibody libraries. Proc Natl Acad Sci. 2012;109(39):15728–33. doi:https://doi.org/10.1073/pnas.1214275109.
   PubMedGoogle Scholar
• Beerli RR, Bauer M, Buser RB, Gwerder M, Muntwiler S, Maurer P, Saudan P, Bachmann MF. Isolation of human monoclonal antibodies by mammalian cell display. Proc Natl Acad Sci U S A. 2008;105(38):14336–41. doi:https://doi.org/10.1073/pnas.0805942105.
   PubMed Web of Science ®Google Scholar
• Breous-Nystrom E, Schultze K, Meier M, Flueck L, Holzer C, Boll M, Seibert V, Schuster A, Blanusa M, Schaefer V. Retrocyte Display® technology: generation and screening of a high diversity cellular antibody library. Methods. 2014;65(1):57–67. doi:https://doi.org/10.1016/j.ymeth.2013.09.003.
   PubMed Web of Science ®Google Scholar
• Waldmeier L, Hellmann I, Gutknecht CK, Wolter FI, Cook SC, Reddy ST, Grawunder U, Beerli RR. Transpo-mAb display: transposition-mediated B cell display and functional screening of full-length IgG antibody libraries. mAbs. 2016;8(4):726–40. doi:https://doi.org/10.1080/19420862.2016.1160990.
   PubMed Web of Science ®Google Scholar
• Haghparast SM, Kihara T, Miyake J. Distinct mechanical behavior of HEK293 cells in adherent and suspended states. PeerJ. 2015;3:e1131. doi:https://doi.org/10.7717/peerj.1131.
   PubMedGoogle Scholar
• Sun Z, Brodsky JL. Protein quality control in the secretory pathway. J Cell Biol. 2019;218:3171–87.
   PubMed Web of Science ®Google Scholar
• Rivera VM. Regulation of protein secretion through controlled aggregation in the endoplasmic reticulum. Science. 2000;287(5454):826–30. doi:https://doi.org/10.1126/science.287.5454.826.
   PubMed Web of Science ®Google Scholar
• Apaja PM, Lukacs GL. Protein homeostasis at the plasma membrane. Physiology (Bethesda). 2014;29:265–77.
   PubMed Web of Science ®Google Scholar
• Boder ET, Wittrup KD. Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol. 1997;15(6):553–57. doi:https://doi.org/10.1038/nbt0697-553.
   PubMed Web of Science ®Google Scholar
• Dupres V, Dufrene YF, Heinisch JJ. Measuring cell wall thickness in living yeast cells using single molecular rulers. ACS Nano. 2010;4(9):5498–504. doi:https://doi.org/10.1021/nn101598v.
   PubMedGoogle Scholar
• McMahon C, Baier AS, Pascolutti R, Wegrecki M, Zheng S, Ong JX, Erlandson SC, Hilger D, Rasmussen SGF, Ring AM, et al. Yeast surface display platform for rapid discovery of conformationally selective nanobodies. Nat Struct Mol Biol. 2018;25(3):289–96. doi:https://doi.org/10.1038/s41594-018-0028-6.
   PubMedGoogle Scholar
• Schuck P, Zhao H. The role of mass transport limitation and surface heterogeneity in the biophysical characterisation of macromolecular binding processes by SPR biosensing. Methods Mol Biol. 2010;627:15–54.
   PubMedGoogle Scholar
• Molecular Operating Environment (MOE). Chemical computing group ULC. 1010 Sherbrooke St. West (Suite #910, Montreal, QC, Canada); Chemical Computing Group; 2019. p. H3A 2R7.
   Google Scholar
• Kieke MC, Shusta EV, Boder ET, Teyton L, Wittrup KD, Kranz DM. Selection of functional T cell receptor mutants from a yeast surface-display library. Proc Natl Acad Sci U S A. 1999;96(10):5651–56. doi:https://doi.org/10.1073/pnas.96.10.5651.
   PubMedGoogle Scholar
• Jones TD, Phillips WJ, Smith BJ, Bamford CA, Nayee PD, Baglin TP, Gaston JSH, Baker MP.Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII. J Thromb Haemost. 2005;3(5):991–1000. doi:https://doi.org/10.1111/j.1538-7836.2005.01309.x.
   PubMedGoogle Scholar
• Quah BJ, Warren HS, Parish CR. Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester. Nat Protoc. 2007;2(9):2049–56. doi:https://doi.org/10.1038/nprot.2007.296.
   PubMed Web of Science ®Google Scholar